表紙
市場調査レポート

ニードルフリー・ドラッグデリバリーの世界市場の将来展望 (2020年まで)

Global Needle Free Drug Delivery Market Outlook 2020

発行 RNCOS E-Services Pvt. Ltd. 商品コード 330510
出版日 ページ情報 英文 80 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
ニードルフリー・ドラッグデリバリーの世界市場の将来展望 (2020年まで) Global Needle Free Drug Delivery Market Outlook 2020
出版日: 2015年05月01日 ページ情報: 英文 80 Pages
概要

ニードルフリー (無針) ドラッグデリバリー技術は、皮膚を傷つけることなく人体に薬剤を送達できるという革新的な技術です。この数年間で、ニードルフリー・ドラッグデリバリー業界は急激な成長の波に乗り、参入企業に巨大な市場機会をもたらしています。良好な人口構造や経済情勢、認知度の上昇にも支えられて、世界のニードルフリー・ドラッグデリバリー市場は更なる規模拡大へと動いています。更に、活発な企業合併・買収 (M&A) 活動や、最新装置 (マイクロニードル (顕微針)・パッチ・ローラーなど) の開発・導入、新規企業の参入といった現象が、市場の一層の拡大を促しています。

当レポートでは、全世界のニードルフリー・ドラッグデリバリー (薬剤送達) 市場について分析し、市場の全体的構造や最新動向、主な市場促進・阻害要因、世界各国の規制・支援策、今後の市場動向の見通し、技術別・用途別・地域別の詳細動向、今後の産業発展の方向性、主要企業のプロファイルなどを調査しております。

第1章 アナリストの見解

第2章 分析手法

第3章 市場促進要因

  • 慢性疾患の発症者数の増加
  • 入手可能性の改善
  • 従来型のドラッグデリバリ装置に対する利点
  • 新興国市場での成長

第4章 市場の課題

  • 価格の高さ
  • 検証・規制に関わる課題
  • 認知度の低さ

第5章 規制環境

  • 米国
  • 欧州
  • 日本
  • 中国
  • インド

第6章 ニードルフリー・ドラッグデリバリー市場の将来展望 (2020年まで)

  • 現在の市場規模と将来の見通し

第7章 市場の内訳

  • 技術別
    • 経口式ドラッグデリバリー・システム
    • 吸入式ドラッグデリバリー・システム
    • 経皮式ドラッグデリバリー・システム
    • ジェット注射器式ドラッグデリバリー・システム
    • マイクロニードル式ドラッグデリバリー・システム
  • 用途別
  • 地域別

第8章 産業動向

  • 発展途上国での低コスト吸入器の導入
  • 最新型の乾燥粉末吸入器の開発
  • 経口式ドラッグデリバリー・システムの電子化
  • 市場再編

第9章 企業プロファイル

  • Mylan Inc.
  • 3M (MMM)
  • Novatis
  • AstraZeneca Plc
  • Antares Pharma, Inc.
  • GlaxoSmithKline Plc (GSK)
  • Sanofi
  • Boehringer Ingelheim GmbH
  • Merck & Co.

図表一覧

目次

The needle-free drug delivery technology is an innovative technique to deliver drugs into a person's body without piercing the skin. The global needle-free drug delivery industry has been riding the tidal waves for the past few years, growing swiftly and presenting ample opportunities to the industry's players. With favorable demographics, positive eco-financial dynamics, and rising awareness, the global needle-free drug delivery market is poised to scale newer acmes. Moreover, augmented M&A activity in the industry, introduction of novel needle-free drug delivery devices, like micro needles, patch and roller, and entry of new players are set to further boost the market's growth.

The latest research by RNCOS titled, "Global Needle Free Drug Delivery Market Outlook 2020", unfolds the market dynamics of the needle-free drug delivery market. In this report, the global needle-free drug delivery industry has been split into five distinct segments viz.: Jet injectors, Transdermal Patches, Micro Needles, and Oral and Inhalation drug delivery, with their current and future outlook to 2020 depicted. The transdermal patches and inhalation drug delivery system markets are further divided into sub-segments, with each segment scrutinized in detail. The report identifies and highlights the segments that offer the maximum opportunity for growth in the global market.

Our industry analysts studied all the facets of the global needle-free drug delivery market to portray a crystal clear picture of the current as well as expected future market outlook. Major drivers and trends have been identified that will act as catalysts towards boosting the industry's growth along with roadblocks hindering the market's growth. The study also delves into the regulatory environment affecting the needle-free drug delivery devices in a number of countries.

It further highlights the competitive landscape of the global needle-free drug delivery market, describing the business, financials, strengths and weaknesses, and recent developments of major industry players, thus helping the reader to gain a crucial insight into the key market players' performances and strategies for growth. Holistically, the research provides all the prerequisite information for clients looking to make a debut in this industry and facilitates them to formulate schemes while going for an investment/partnership in the global needle-free drug delivery industry.

Table of Contents

1. Analyst View

2. Research Methodology

3. Drivers

  • 3.1 Increasing Incidence of Chronic Diseases
  • 3.2 Increased Affordability
  • 3.3 Benefits over Conventional Drug Delivery Devices
  • 3.4 Expansion in Emerging Markets

4. Challenges

  • 4.1 High Prices
  • 4.2 Testing and Regulatory Issues
  • 4.3 Low Awareness

5. Regulatory Landscape

  • 5.1 US
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China
  • 5.5 India

6. Needle Free Drug Delivery Market Outlook to 2020

  • 6.1 Current Market size and Future Outlook

7. Market Segmentation

  • 7.1 By Technology
    • 7.1.1 Oral Drug Delivery System
    • 7.1.2 Inhaler Drug Delivery System
    • 7.1.3 Transdermal Drug Delivery System
    • 7.1.4 Jet injector Drug Delivery System
    • 7.1.5 Micro Needle Drug Delivery System
  • 7.2 By Application
  • 7.3 By geography

8. Industry Trends

  • 8.1 Introduction of Low Cost Inhalers for Developing Countries
  • 8.2 Innovation in Advanced Dry Powder Inhalers
  • 8.3 Oral Drug Delivery System goes Electrical
  • 8.4 Consolidation in the Market

9. Competitor Profiles

  • 9.1 Mylan Inc.
  • 9.2 3M (MMM)
  • 9.3 Novatis
  • 9.4 AstraZeneca Plc
  • 9.5 Antares Pharma, Inc.
  • 9.6 GlaxoSmithKline Plc (GSK)
  • 9.7 Sanofi
  • 9.8 Boehringer Ingelheim GmbH
  • 9.9 Merck & Co.

List of Figures:

  • Figure 6-1: Global - Needle Free Drug Delivery Market (Billion US$), 2014-2020
  • Figure 7-1: Global - Needle Free Drug Delivery Market by Technology (%), 2014
  • Figure 7-2: Global - Oral Drug Delivery Market (Billion US$), 2014-2020
  • Figure 7-3: Global - Inhaler Drug Delivery Market (Billion US$), 2014-2020
  • Figure 7-4: Global - Inhaler Drug Delivery Market by Segment (%), 2014
  • Figure 7-5: Global - Inhaled Drug Delivery Market by Players (%), 2013
  • Figure 7-6: Global - Transdermal Drug Delivery Market (Billion US$), 2014-2020
  • Figure 7-7: Global - Transdermal Drug Delivery Market by Sub-Segment (%), 2013
  • Figure 7-8: Global - Jet Injectors Market (Million US$), 2014-2020
  • Figure 7-9: Global - Jet Injectors Market by Players (%), 2014
  • Figure 7-10: Global - Needle Free Drug Delivery Market by Application (%), 2014
  • Figure 7-11: Global - Needle Free Drug Delivery Market by Region (%), 2014
  • Figure 9-1: Mylan - Breakup of Revenue by Geography (%), 2014
  • Figure 9-2: 3M - Breakup of Revenue by Geography (%), 2014
  • Figure 9-3: Novartis - Breakup of Revenue by Geography (%), 2014
  • Figure 9-4: AstraZeneca Plc - Breakup of Revenue by Geography (%), 2014
  • Figure 9-5: Antares Pharma Inc. - Breakup of Revenue by Geography (%), 2014
  • Figure 9-6: GlaxoSmithKline Plc - Breakup of Revenue by Geography (%), 2014
  • Figure 9-7: Sanofi - Breakup of Revenue by Geography (%), 2014
  • Figure 9-8: Boehringer Ingelheim GmbH - Breakup of Revenue by Geography (%), 2013
  • Figure 9-9: Merck & Co - Breakup of Revenue by Geography (%), 2014

List of Tables:

  • Table 7-1: Oral Drug Delivery - Pipeline Analysis (2014)
  • Table 7-2: Inhaled Drug Delivery - Pipeline Analysis (2014)
  • Table 7-3: Transdermal Drug Delivery - Pipeline Analysis (2014)
  • Table 7-4: Jet Injectors Drug Delivery - Pipeline Analysis (2014)
  • Table 7-5: Micro Needles Drug Delivery - Pipeline Analysis (2014)
  • Table 8-1: Recent M&A in the Needle Free Drug Delivery Industry (2014)
  • Table 9-1: Mylan - Key Financials (Million US$), 2012-2014
  • Table 9-2: Mylan - Strengths and Weaknesses
  • Table 9-3: 3M - Key Financials (Million US$), 2012-2014
  • Table 9-4: 3M - Strengths and Weaknesses
  • Table 9-5: Novartis - Key Financials (Million US$), 2012-2014
  • Table 9-6: Novartis - Strengths and Weaknesses
  • Table 9-7: AstraZeneca Plc - Key Financials (Million US$), 2012-2014
  • Table 9-8: Astrazeneca - Strengths and Weaknesses
  • Table 9-9: Antares Pharma Inc. - Key Financials (Million US$), 2012-2014
  • Table 9-10: GlaxoSmithKline Plc - Key Financials (Million US$), 2012-2014
  • Table 9-11: GlaxoSmithKline - Strengths and Weaknesses
  • Table 9-12: Sanofi - Key Financials (Million US$), 2012-2014
  • Table 9-13: Sanofi - Strengths and Weaknesses
  • Table 9-14: Boehringer Ingelheim GmbH- Key Financials, (Million US$), 2011-2013
  • Table 9-15: Boehringer Ingelheim GmbH - Strengths and Weaknesses
  • Table 9-16: Merck & Co- Key Financials (Million US$), 2012-2014
  • Table 9-17: Merck & Co- Strengths and Weaknesses
Back to Top